Phenotypes Associated with This Genotype

Genotype
MGI:5689882

• Allelic Composition: Tg(Alb1HBV)44Bri/0
• Genetic Background: C57BL/6J-Tg(Alb1HBV)44Bri/J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

neoplasm

increased incidence of tumors by chemical induction ( J:223921 )

• mice injected with the hepatotoxin AFB1 develop nodules at 6 months after treatment; more nodules are seen in mice treated with AFB1 than in untreated mice and most nodules are large

• abundance and size of liver lesions in adults exposed to AFB1 increase over time after treatment and AFB1 treatment accelerates the liver lesions in older mice

• male neonates exposed to AFB1 show a tendency to develop lesions earlier than females, however, by 15 months, females have an about equal frequency of liver lesions as males

• mice injected with AFB1 at day 7 develop regenerative foci, adenoma, and carcinoma as do mice injected with AFB1 in adulthood but much more frequently

increased liver tumor incidence ( J:223921 )

• mice develop nodules in the liver at 9 months of age; nodules are mostly small although some large ones develop

increased hepatocellular carcinoma incidence ( J:223921 )

• end-stage liver tumors are molecularly similar and resemble hepatocellular carcinoma

increased liver adenoma incidence ( J:223921 )

• mice develop only regenerative foci or adenomas at 15 months of age

homeostasis/metabolism

increased incidence of tumors by chemical induction ( J:223921 )

• mice injected with the hepatotoxin AFB1 develop nodules at 6 months after treatment; more nodules are seen in mice treated with AFB1 than in untreated mice and most nodules are large

• abundance and size of liver lesions in adults exposed to AFB1 increase over time after treatment and AFB1 treatment accelerates the liver lesions in older mice

• male neonates exposed to AFB1 show a tendency to develop lesions earlier than females, however, by 15 months, females have an about equal frequency of liver lesions as males

• mice injected with AFB1 at day 7 develop regenerative foci, adenoma, and carcinoma as do mice injected with AFB1 in adulthood but much more frequently

immune system

liver inflammation ( J:223921 )

• mice develop overt liver lesions (hepatitis) beginning from 9-12 months of age

• mice injected with the hepatotoxin AFB1 develop a large number of liver lesions that are obvious from 9 months after treatment

• mice injected with AFB1 at adulthood show an increase in liver lesions compared with untreated mice

• males are more susceptible to liver lesions much earlier than females when adults are injected with AFB1 at 6 months, although by 5 months, similar incidence rates are seen for both genders

liver/biliary system

liver inflammation ( J:223921 )

• mice develop overt liver lesions (hepatitis) beginning from 9-12 months of age

• mice injected with the hepatotoxin AFB1 develop a large number of liver lesions that are obvious from 9 months after treatment

• mice injected with AFB1 at adulthood show an increase in liver lesions compared with untreated mice

• males are more susceptible to liver lesions much earlier than females when adults are injected with AFB1 at 6 months, although by 5 months, similar incidence rates are seen for both genders

increased liver tumor incidence ( J:223921 )

• mice develop nodules in the liver at 9 months of age; nodules are mostly small although some large ones develop

increased hepatocellular carcinoma incidence ( J:223921 )

• end-stage liver tumors are molecularly similar and resemble hepatocellular carcinoma

increased liver adenoma incidence ( J:223921 )

• mice develop only regenerative foci or adenomas at 15 months of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
hepatocellular carcinoma		DOID:684	OMIM:114550	J:223921